Overview
Palbociclib is an oral cyclin-dependent kinase (CDK) 4/6 inhibitor that regulates cell-cycle progression by blocking the CDK4/6 pathway. It helps prevent cancer cells from progressing through the cell cycle and is used in combination with endocrine therapy for eligible patients with HR-positive, HER2-negative advanced or metastatic breast cancer.